Marks Group Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
Marks Group Wealth Management's ALNY Position: Q3 2026 in Review
Marks Group Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 279% in Q3 2026, buying an estimated $1.93M and bringing the position to 10,307 shares worth $2.54M. The position accounts for 0.22% of the portfolio, ranked #113.
Marks Group Wealth Management first reported a position in ALNY in Q1 2026 and has held it in 3 quarters since. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- Marks Group Wealth Management held 10,307 shares of Alnylam Pharmaceuticals worth $2.54M as of Q3 2026.
- Marks Group Wealth Management bought 7,590 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $1.93M.
- Alnylam Pharmaceuticals made up 0.22% of Marks Group Wealth Management's portfolio in Q3 2026, its #113 holding.
- Marks Group Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on Marks Group Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.